Premium
Review article: the treatment of functional abdominal bloating and distension
Author(s) -
Schmulson M.,
Chang L.
Publication year - 2011
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2011.04637.x
Subject(s) - bloating , medicine , irritable bowel syndrome , placebo , lubiprostone , gastroenterology , tegaserod , flatulence , abdominal pain , constipation , abdominal distension , rifaximin , distension , clinical endpoint , randomized controlled trial , chronic constipation , pathology , antibiotics , alternative medicine , microbiology and biotechnology , biology
Aliment Pharmacol Ther 2011; 33: 1071–1086 Summary Background Abdominal bloating and distension are common symptoms in patients with functional gastrointestinal disorders (FGIDs), however, relatively little is known about their treatment. Aim To review the treatment trials for abdominal bloating and distension. Methods A literature review in Medline for English‐language publications through February 2010 of randomised, controlled treatment trials in adults. Study quality was assessed according to Jadad’s score. Results Of the 89 studies reviewed, 18% evaluated patients with functional dyspepsia, 61% with irritable bowel syndrome (IBS), 10% with chronic constipation and 10% with other FGIDs. No studies were conducted in patients diagnosed with functional abdominal bloating. The majority of trials investigated the efficacy of prokinetics or probiotics, although studies are heterogeneous with respect to diagnostic criteria and outcome measures. In general, bloating and/or distension were evaluated as secondary endpoints or as individual symptoms as part of a composite score rather than as primary endpoints. A greater proportion of IBS patients with constipation reported improvement in bloating with tegaserod vs. placebo (51% vs. 40%, P < 0.0001) and lubiprostone ( P < 0.001). A greater proportion of nonconstipating IBS patients reported adequate relief of bloating with rifaximin vs. placebo (40% vs. 30%, P < 0.001). Bloating was significantly reduced with the probiotics, Bifidobacterium infantis 35624 (1 × 10 8 dose vs. placebo: −0.71 vs. −0.44, P < 0.05) and B. animalis (live vs. heat‐killed: −0.56 ± 1.01 vs. −0.31 ± 0.87, P = 0.03). Conclusions Prokinetics, lubiprostone, antibiotics and probiotics demonstrate efficacy for the treatment of bloating and/or distension in certain FGIDs, but other agents have either not been studied adequately or have shown conflicting results.